Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • thejustpark
    Member
    • Jul 2012
    • 28

    #1

    still too many differentially expressed genes.

    Hello,

    I am doing a DE analysis on TCGA BRCA data.
    In particular, I took 85 tumor-normal pairs from the data and am trying to figure out which genes are differentially expressed.
    And surprisingly, I found that at least 9,000 out of 20,000 genes are.
    So my question is if my analysis with this radical number can be right, and if not, what's wrong in the process.

    To this end, I am employing the step 14 suggested in S. Anders et al. in Nat. Biotech. 2013 (Count-based differential expression analysis of RNA
    sequencing data using R and Bioconductor), especially for pre-processing steps. Since DESeq2 is not mentioned, I did the analysis only with edgeR. Attached are the figures from plotMDS,plotMeanVar,plotBCS, and plotSmear functions according to the suggestion. I think they imply my analysis can be right, in the sense that many tagwise variations are less than common variation and the cases are separated quite well in MDS.

    Interestingly, my another DE analysis using a widely-known non-parametric tool, SAMSeq, suggests around similar number of DE genes.

    Again, can my analysis be OK? but I have never seen this kind of case with this number of DE genes.
    So if my analysis is not correct, can you please tell me what's wrong?
    Thanks in advance.
    Attached Files
  • dietmar13
    Senior Member
    • Mar 2010
    • 107

    #2
    yes, why not.

    what do you think, how many genes are differentially expressed between normal tissues (what is exactly the normal progenitor - the lobular or ductal epithelial cell - and where is the stroma, where are the blood and lymph vessels, ...) and the cancerous tissue (a mixture of cancer cells and cancerous remodelled microenvironment, like tumor stroma, cancer specific immune cells, ...).

    i would suspect, that ALL genes are differentially expressed between tumor tissue (mixtures) and normal tissue (mixtures).

    the number you get are reliable, IMHO.

    the problem is that (all) normalization methods and many statistical methods rely on the assumption that most of the genes are not differentially expressed - which is violated in comparison of such different tissue-mixtures.

    and another problem is that absolute expression heights matter, and not relative (to stably expressed genes, if such genes exist at all)...

    dietmar

    Comment

    • thejustpark
      Member
      • Jul 2012
      • 28

      #3
      Thank you dietmar13,

      Your comments are very insightful.
      So what you are saying is that this can be actually a case that this number of genes are DEed in TCGA BRCA between tumor and normal even with its heterogeneity. Then, it is strange why this obvious and global pattern were not reported in a literature. Hm.....

      But as for the problem you raised about the assumption of statistical methods that most genes are DEed, that is why I did this analysis again using SAMSeq, a sampling based DE analysis tool that (I believe to ) inspect each gene individually.
      When SAMSeq returns a similar number of DE genes, I take it is not a problem.
      What do you think?

      HJ.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        07-31-2026, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 08-06-2026, 07:41 AM
      0 responses
      14 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 08-03-2026, 10:13 AM
      0 responses
      31 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-31-2026, 02:55 AM
      0 responses
      40 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      26 views
      0 reactions
      Last Post SEQadmin2  
      Working...